Pathological differences between white and grey matter multiple sclerosis lesions

Annals of the New York Academy of Sciences

Volumn 1351, Issue 1, 2015, Pages 99-113

  Prins, Marloes ^a   Schul, Emma ^a   Geurts, Jeroen ^a   van der Valk, Paul ^b   Drukarch, Benjamin ^a   van Dam, Anne Marie ^a  

^a Department of Anatomy and Neurosciences ^*  (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Grey matter lesion; Inflammation; Multiple sclerosis; White matter lesion

Indexed keywords

MYELIN; NEUROTRANSMITTER;

ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DEMYELINATION; DISEASE ASSOCIATION; GLIA CELL; GRAY MATTER; GREY MATTER LESION; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; MICROGLIA; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; WHITE MATTER; WHITE MATTER LESION; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEMYELINATING DISEASE; IMMUNOLOGY; INFLAMMATION; LEUKOENCEPHALOPATHY; PATHOLOGY; PATHOPHYSIOLOGY;

ASTROCYTES; BLOOD-BRAIN BARRIER; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEMYELINATING DISEASES; GRAY MATTER; HUMANS; INFLAMMATION; LEUKOENCEPHALOPATHIES; MICROGLIA; MULTIPLE SCLEROSIS; WHITE MATTER;

EID: 84941808746     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12841     Document Type: Article

References (164)

1. Noseworthy, J., C. Lucchinetti, M. Rodriguez, et al. 2000. Multiple sclerosis. N. Engl. J. Med. 372: 1502-1517.
2. Lassmann, H. 2011. Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathol. Appl. Neurobiol. 37: 698-710.
3. Tallantyre, E.C., L. Bø, O. Al-Rawashdeh, et al. 2010. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult. Scler. 16: 406-411.
4. McDonald, W.I. & D. Barnes 1992. The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system. J. Neurol. Neurosurg. Psychiatry 55: 747-752.
5. Balcer, L.J. 2006. Optic Neuritis. N. Engl. J. Med. 354: 1273-1280.
6. Cruccu, G., A. Biasiotta, S. Di Rezze, et al. 2009. Trigeminal neuralgia and pain related to multiple sclerosis. Pain 143: 186-191.
7. Coelho, A., B. Ceranic, D. Prasher, et al. 2007. Auditory efferent function is affected in multiple sclerosis. Ear Hear. 28: 593-604.
8. Prosperini, L., A. Kouleridou, N. Petsas, et al. 2011. The relationship between infratentorial lesions, balance deficit and accidental falls in multiple sclerosis. J. Neurol. Sci. 304: 55-60.
9. Papadopoulos, A., S. Gatzonis, A. Gouliamos, et al. 1994. Correlation between spinal cord MRI and clinical features in patients with demyelinating disease. Neuroradiology 36: 130-133.
10. Zackowski, K.M., S.A. Smith, D.S. Reich, et al. 2009. Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 132: 1200-1209.
11. Kalkers, N.F., R.L.M. Strijers, M.M.S. Jasperse, et al. 2007. Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. Clin. Neurophysiol. 118: 1332-1340.
12. Bjartmar, C., G. Kidd, S. Mörk, et al. 2000. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48: 893-901.
13. Bakshi, R. 2003. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult. Scler. 9: 219-227.
14. Comi, G., L. Leocani, P. Rossi, et al. 2001. Physiopathology and treatment of fatigue in multiple sclerosis. J. Neurol. 248: 174-179.
15. Induruwa, I., C.S. Constantinescu & B. Gran 2012. Fatigue in multiple sclerosis: a brief review. J. Neurol. Sci. 323: 9-15.
16. Chiaravalloti, N.D. & J. DeLuca 2008. Cognitive impairment in multiple sclerosis. Lancet Neurol. 7: 1139-1151.
17. Rao, S., G. Leo, L. Bernardin, et al. 1991. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41: 685-691.
18. Amor, S., F. Puentes, D. Baker, et al. 2010. Inflammation in neurodegenerative diseases. Immunology 129: 154-169.
19. Stadelmann, C., C. Wegner & W. Brück 2011. Inflammation, demyelination, and degeneration: recent insights from MS pathology. Biochim. Biophys. Acta 1812: 275-282.
20. Barnett, M.H. & J.W. Prineas 2004. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55: 458-468.
21. Henderson, A.P., M.H. Barnett, J.D. Parratt, et al. 2009. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol. 66: 739-753.
22. Lucchinetti, C., W. Brück, J. Parisi, et al. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47: 707-717.
23. Marik, C., Pa. Felts, J. Bauer, et al. 2007. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130: 2800-2815.
24. Dhib-Jalbut, S. & S. Marks 2010. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74(Suppl 1): S17-24.
25. Trapp, B.D. & K.-A. Nave 2008. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 31: 247-269.
26. Stys, P.K., G.W. Zamponi, J. van Minnen, et al. 2012. Will the real multiple sclerosis please stand up? Nat. Rev. Neurosci. 13: 507-514.
27. Way, S.W., J.R. Podojil, B.L. Clayton, et al. 2015. Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic. Nat. Commun. 6: 6532.
28. Van der Valk, P. & C.J. De Groot 2000. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol. Appl. Neurobiol. 26: 2-10.
29. Bö, L., S. Mörk, Pa. Kong, et al. 1994. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J. Neuroimmunol. 51: 135-146.
30. Trapp, B.D., J. Peterson, R.M. Ransohoff, et al. 1998. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338: 278-285.
31. Bø, L., C. Vedeler, H. Nyland, et al. 2003. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 9: 323-331.
32. Peterson, J.W., L. Bö, S. Mörk, et al. 2001. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50: 389-400.
33. Kolbe, S.C., M. Marriott, A. Van Der Walt, et al. 2012. Diffusion tensor imaging correlates of visual impairment in multiple sclerosis and chronic optic neuritis. Invest. Ophthalmol. Vis. Sci. 53: 825-832.
34. Charil, A., A.P. Zijdenbos, J. Taylor, et al. 2003. Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. Neuroimage 19: 532-544.
35. De Groot, V., H. Beckerman, B.M. Uitdehaag, et al. 2009. Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis. Arch. Phys. Med. Rehabil. 90: 1478-1488.
36. Popescu, B.F.G. & C.F. Lucchinetti 2012. Pathology of Demyelinating Diseases. Annu. Rev. Pathol. 7: 185-217.
37. Van Waesberghe, J.H., W. Kamphorst, C.J. De Groot, et al. 1999. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann. Neurol. 46: 747-754.
38. Van der Valk, P. & S. Amor 2009. Preactive lesions in multiple sclerosis. Curr. Opin. Neurol. 22: 207-213.
39. Singh, S., I. Metz, S. Amor, et al. 2013. Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol. 125: 595-608.
40. Barkhof, F. 2002. The clinico-radiological paradox in multiple sclerosis revisited. Curr. Opin. Neurol. 15: 239-245.
41. Kutzelnigg, A., C.F. Lucchinetti, C. Stadelmann, et al. 2005. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128: 2705-2712.
42. Lucchinetti, C.F., B.F.G. Popescu, R.F. Bunyan, et al. 2011. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365: 2188-2197.
43. Bö, L., J.J.G. Geurts, P. van der Valk, et al. 2007. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch. Neurol. 64: 76-80.
44. Bagnato, F., J.A. Butman, S. Gupta, et al. 2006. In vivo detection of cortical plaques by MR. Am. J. Neuroradiol. 27: 2161-2167.
45. Calabrese, M., M.A. Rocca, M. Atzori, et al. 2009. Cortical lesions in primary progressive multiple sclerosis A 2-year longitudinal MR study. Neurology 72: 1330-1336.
46. Filippi, M., P. Preziosa, E. Pagani, et al. 2013. Microstructural magnetic resonance imaging of cortical lesions in multiple sclerosis. Mult. Scler. 19: 418-426.
47. Sethi, V., T.A. Yousry, N. Muhlert, et al. 2012. Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J. Neurol. Neurosurg. Psychiatry 83: 877-882.
48. Calabrese, M., N. De Stefano, M. Atzori, et al. 2007. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch. Neurol. 64: 1416.
49. Gilmore, C.P., I. Donaldson, L. Bö, et al. 2009. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J. Neurol. Neurosurg. Psychiatry 80: 182-187.
50. Kutzelnigg, A., C.F. Lucchinetti, C. Stadelmann, et al. 2005. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128: 2705-2712.
51. Vercellino, M., F. Plano, B. Votta, et al. 2005. Grey matter pathology in multiple sclerosis. J. Neuropathol. Exp. Neurol. 64: 1101-1107.
52. Geurts, J.J., L. Bo, S.D. Roosendaal, et al. 2007. Extensive hippocampal demyelination in multiple sclerosis. J. Neuropathol. Exp. Neurol. 66: 819-827.
53. Papadopoulos, D., S. Dukes, R. Patel, et al. 2009. Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Brain Pathol. 19: 238-253.
54. Kutzelnigg, A., J.C. Faber-Rod, J. Bauer, et al. 2007. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 17: 38-44.
55. Benedict, R.H.B., D. Ramasamy, F. Munschauer, et al. 2009. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J. Neurol. Neurosurg. Psychiatry 80: 201-206.
56. Hulst, H.E., M.M. Schoonheim, S.D. Roosendaal, et al. 2012. Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. Hum. Brain Mapp. 33: 2268-2280.
57. Feinstein, A., P. Roy, N. Lobaugh, et al. 2004. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62: 586-590.
58. Feuillet, L., F. Reuter, B. Audoin, et al. 2007. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult. Scler. 13: 124-127.
59. Schulz, D., B. Kopp, A. Kunkel, et al. 2006. Cognition in the early stage of multiple sclerosis. J. Neurol. 253: 1002-1010.
60. Haase, C.G., M. Tinnefeld, M. Lienemann, et al. 2003. Depression and cognitive impairment in disability-free early multiple sclerosis. Behav. Neurol. 14: 39-45.
61. Bø, L., Ca. Vedeler, H.I. Nyland, et al. 2003. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 62: 723-732.
62. Booss, J., M.M. Esiri, W.W. Tourtellotte, et al. 1983. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J. Neurol. Sci. 62: 219-232.
63. Wucherpfennig, B.K.W., J. Newcombe, H. Li, et al. 1992. T Cell receptor Valpha-Vbeta repertoire and cytokine gene expression in active multiple sclerosis lesions. J. Exp. Med. 175: 993-1002.
64. Disanto, G., J.M. Morahan, M.H. Barnett, et al. 2012. The evidence for a role of B cells in multiple sclerosis. Neurology 78: 823-832.
65. Kaur, G., J. Trowsdale & L. Fugger 2013. Natural killer cells and their receptors in multiple sclerosis. Brain 136: 2657-2676.
66. Sospedra, M. & R. Martin 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747.
67. Bar-Or, A. & P.J. Darlington 2011. "The immunology of multiple sclerosis." In Multiple Sclerosis Therapeutics, 4th ed. J.A. Cohen & R.A. Rudick, Eds.: 20-34. Cambridge: Cambridge University Press.
68. Fletcher, J.M., S.J. Lalor, C.M. Sweeney, et al. 2010. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162: 1-11.
69. Martin, R., H.F. McFarland & D.E. McFarlin 1992. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10: 153-187.
70. Tran, E.H., K. Hoekstra, N. VanRooijen, et al. 1998. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J. Immunol. 161: 3767-3775.
71. Huitinga, I., N. van Rooijen, C.J. de Groot, et al. 1990. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172: 1025-1033.
72. Mosser, D.M. & J.P. Edwards 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
73. Vogel, D.Y.S., E.J.F. Vereyken, J.E. Glim, et al. 2013. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J. Neuroinflammation 10: 35.
74. Traugott, U., E.L. Reinherz & C.S. Raine 1983. Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J. Neuroimmunol. 4: 201-221.
75. McFarland, H.F. & R. Martin 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8: 913-919.
76. + T cells in inflammatory demyelinating disease. J. Neuroimmunol. 191: 79-85.
77. O'Connor, R.A., C.T. Prendergast, A. Catherine, et al. 2008. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 181: 3750-3754.
78. Furtado, G.C., M.C.G. Marcondes, J. Tsai, et al. 2008. Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis. J. Immunol. 181: 4648-4655.
79. Murphy, Á.C., S.J. Lalor, M.A. Lynch, et al. 2010. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain. Behav. Immun. 24: 641-651.
80. Owens, T., I. Bechmann & B. Engelhardt 2008. Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 67: 1113-1121.
81. Ballabh, P., A. Braun & M. Nedergaard 2004. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16: 1-13.
82. Zlokovic, B.V. 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201.
83. Ley, K., C. Laudanna, M.I. Cybulsky, et al. 2007. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7: 678-689.
84. Kebir, H., K. Kreymborg, I. Ifergan, et al. 2007. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13: 1173-1175.
85. Agrawal, S., P. Anderson, M. Durbeej, et al. 2006. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203: 1007-1019.
86. Metz, I., C.F. Lucchinetti, H. Openshaw, et al. 2007. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 130: 1254-1262.
87. Nimmerjahn, A., F. Kirchhoff & F. Helmchen 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308: 1318-1318.
88. Aguzzi, A., Ba. Barres & M.L. Bennett 2013. Microglia: scapegoat, saboteur, or something else? Science 339: 156-161.
89. Benarroch, E.E. 2013. Microglia: Multiple roles in surveillance, circuit shaping, and response to injury. Neurology 81: 1079-1088.
90. Jack, C., J. Antel & W.B.R. Uck 2007. Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis. Glia 55: 926-934.
91. Stadelmann, C., M. Kerschensteiner, T. Misgeld, et al. 2002. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125: 75-85.
92. Farina, C., F. Aloisi & E. Meinl 2007. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28: 138-145.
93. Dong, Y. & E.N. Benveniste 2001. Immune function of astrocytes. Glia 190: 180-190.
94. Ponomarev, E.D., L.P. Shriver, K. Maresz, et al. 2005. Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J. Neurosci. Res. 81: 374-389.
95. D'Amelio, F.E., M.E. Smith & L.F. Eng 1990. Sequence of tissue responses in the early stages of experimental allergic encephalomyelitis EAE: immunohistochemical, light microscopic, and ultrastructural observations in the spinal cord. Glia 3: 229-240.
96. Morcos, Y., S.M. Lee & M.C. Levin 2003. A role for hypertrophic astrocytes and astrocyte precursors in a case of rapidly progressive multiple sclerosis. Mult. Scler. 9: 332-341.
97. Heppner, F.L., M. Greter, D. Marino, et al. 2005. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11: 146-152.
98. Xiao, Y., J. Jin, M. Chang, et al. 2013. Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nat. Med. 19: 595-602.
99. Skripuletz, T., D. Hackstette, K. Bauer, et al. 2013. Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 136: 147-167.
100. Kotter, M.R., C. Zhao, N. van Rooijen, et al. 2005. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol. Dis. 18: 166-175.
101. Voss, E.V., J. Škuljec, V. Gudi, et al. 2012. Characterisation of microglia during de- and remyelination: can they create a repair promoting environment? Neurobiol. Dis. 45: 519-528.
102. Rawji, K.S. & V.W. Yong 2013. The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin. Dev. Immunol. 2013: 1-13.
103. Miljković, D., G. Timotijević & M. Mostarica Stojković 2011. Astrocytes in the tempest of multiple sclerosis. FEBS Lett. 585: 3781-3788.
104. Peferoen, L.A.N., D.Y.S. Vogel, K. Ummenthum, et al. 2015. Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. J. Neuropathol. Exp. Neurol. 74: 48-63.
105. Bø, L. 2009. The histopathology of grey matter demyelination in multiple sclerosis. Acta Neurol. Scand. 120: 51-57.
106. Politis, M., P. Giannetti, P. Su, et al. 2012. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 79: 523-530.
107. Peterson, J.W., L. Bö, S. Mörk, et al. 2002. VCAM-1-positive microglia target oligodendrocytes at the border of multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 61: 539-546.
108. Dal Bianco, A., M. Bradl, J. Frischer, et al. 2008. Multiple sclerosis and Alzheimer's disease. Ann. Neurol. 63: 174-183.
109. Davalos, D., J.K. Ryu, M. Merlini, et al. 2012. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat. Commun. 3: 1227.
110. Di Penta, A., B. Moreno, S. Reix, et al. 2013. Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One 8: e54722.
111. Kooi, E.-J., E.M.M. Strijbis, P. van der Valk, et al. 2012. Heterogeneity of cortical lesions in multiple sclerosis: clinical and pathologic implications. Neurology 79: 1369-1376.
112. Yates, R.L., M.M. Esiri, J. Palace, et al. 2015. The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis. Neuropathol. Appl. Neurobiol. 41: 371-384.
113. Napoli, I. & H. Neumann 2010. Protective effects of microglia in multiple sclerosis. Exp. Neurol. 225: 24-28.
114. Melief, J., K.G. Schuurman, M.D.B. van de Garde, et al. 2013. Microglia in normal appearing white matter of multiple sclerosis are alerted but immunosuppressed. Glia 61: 1848-1861.
115. Boven, L.A., M. Van Meurs, M. Van Zwam, et al. 2006. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129: 517-526.
116. Takahashi, K., C.D.P. Rochford & H. Neumann 2005. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 201: 647-657.
117. Piccio, L., C. Buonsanti, M. Mariani, et al. 2007. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur. J. Immunol. 37: 1290-1301.
118. Kotter, M.R., W.-W. Li, C. Zhao, et al. 2006. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J. Neurosci. 26: 328-332.
119. Petzold, A., M.J. Eikelenboom, D. Gveric, et al. 2002. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125: 1462-1473.
120. Bannerman, P., A. Hahn, A. Soulika, et al. 2007. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia 55: 57-64.
121. Popescu, B.F.G., R.F. Bunyan, J.E. Parisi, et al. 2011. A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology 76: 1705-1710.
122. Clarner, T., F. Diederichs, K. Berger, et al. 2012. Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions. Glia 60: 1468-1480.
123. Prins, M., R. Dutta, B. Baselmans, et al. 2014. Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of multiple sclerosis patients. Acta Neuropathol. Commun. 2: 98.
124. Haider, L., C. Simeonidou, G. Steinberger, et al. 2014. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J. Neurol. Neurosurg. Psychiatry 85: 1386-1395.
125. Giannetti, P., M. Politis, P. Su, et al. 2015. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain 138: 110-119.
126. Calabrese, M., M. Battaglini, A. Giorgio, et al. 2010. Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. Neurology 75: 1234-1240.
127. Van Horssen, J., B.P. Brink, H.E. de Vries, et al. 2007. The blood-brain barrier in cortical multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 66: 321-328.
128. Brink, B.P., R. Veerhuis, E.C.W. Breij, et al. 2005. The pathology of multiple sclerosis is location-d1ependent: no significant complement activation is detected in purely cortical lesions. J. Neuropathol. Exp. Neurol. 64: 147-155.
129. Pham, H., A.A. Ramp, N. Klonis, et al. 2009. The astrocytic response in early experimental autoimmune encephalomyelitis occurs across both the grey and white matter compartments. J. Neuroimmunol. 208: 30-39.
130. Howell, O.W., Ca. Reeves, R. Nicholas, et al. 2011. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134: 2755-2771.
131. Choi, S.R., O.W. Howell, D. Carassiti, et al. 2012. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 135: 2925-2937.
132. Schwartz, M., J. Kipnis, S. Rivest, et al. 2013. How do immune cells support and shape the brain in health, disease, and aging? J. Neurosci. 33: 17587-17596.
133. Dragunow, M. 2013. Meningeal and choroid plexus cells-novel drug targets for CNS disorders. Brain Res. 1501: 32-55.
134. Baruch, K., N. Ron-Harel, H. Gal, et al. 2013. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc. Natl. Acad. Sci. U.S.A. 110: 2264-2269.
135. Reboldi, A., C. Coisne, D. Baumjohann, et al. 2009. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10: 514-523.
136. Biber, K., H. Neumann, K. Inoue, et al. 2007. Neuronal "On" and "Off" signals control microglia. Trends Neurosci. 30: 596-602.
137. Wright, G.J., M. Jones, M.J. Puklavec, et al. 2001. The unusual distribution of the neuronal/lymphoid cell surface CD200 OX2. glycoprotein is conserved in humans. Immunology 102: 173-179.
138. Hernangómez, M., L. Mestre, F.G. Correa, et al. 2012. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia 60: 1437-1450.
139. Smith, R.E., V. Patel, S.D. Seatter, et al. 2003. A novel MyD-1 SIRP-1alpha. signaling pathway that inhibits LPS-induced TNFalpha production by monocytes. Blood 102: 2532-2540.
140. Oldenborg, Pa., H.D. Gresham & F.P. Lindberg 2001. CD47-signal regulatory protein alpha SIRPalpha regulates Fcgamma and complement receptor-mediated phagocytosis. J. Exp. Med. 193: 855-862.
141. Koning, N., D.F. Swaab, R.M. Hoek, et al. 2009. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J. Neuropathol. Exp. Neurol. 68: 159-167.
142. Gitik, M., S. Liraz-Zaltsman, P.-A. Oldenborg, et al. 2011. Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPα signal regulatory protein-α;. on phagocytes. J. Neuroinflammation 8: 24.
143. Koning, N., L. Bö, R.M. Hoek, et al. 2007. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann. Neurol. 62: 504-514.
144. Tian, L., J. Lappalainen, M. Autero, et al. 2008. Shedded neuronal ICAM-5 suppresses T-cell activation. Blood 111: 3615-3625.
145. Harrison, J.K., Y. Jiang, S. Chen, et al. 1998. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U.S.A. 95: 10896-10901.
146. Smolders, J., E.B.M. Remmerswaal, K.G. Schuurman, et al. 2013. Characteristics of differentiated CD8+. and CD4 +. T cells present in the human brain. Acta Neuropathol. 126: 525-535.
147. Cardona, A.E., E.P. Pioro, M.E. Sasse, et al. 2006. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 9: 917-924.
148. Mizuno, T., J. Kawanokuchi, K. Numata, et al. 2003. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 979: 65-70.
149. Traynelis, S.F., L.P. Wollmuth, C.J. Mcbain, et al. 2010. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 62: 405-496.
150. Niswender, C.M. & P.J. Conn 2010. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50: 295-322.
151. Taylor, D.L., L.T. Diemel & J.M. Pocock 2003. Activation of microglial group iii metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J. Neurosci. 23: 2150-2160.
152. Pocock, J.M. & H. Kettenmann 2007. Neurotransmitter receptors on microglia. Trends Neurosci. 30: 527-535.
153. Kukley, M., E. Capetillo-Zarate & D. Dietrich 2007. Vesicular glutamate release from axons in white matter. Nat. Neurosci. 10: 311-320.
154. Jensen, J.E., B.D.B. Frederick & P.F. Renshaw 2005. Grey and white matter GABA level differences in the human brain using two-dimensional, J-resolved spectroscopic imaging. NMR Biomed. 18: 570-576.
155. Gudi, V., D. Moharregh-Khiabani, T. Skripuletz, et al. 2009. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res. 1283: 127-138.
156. Mittelbronn, M., K. Dietz, H.J. Schluesener, et al. 2001. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. 101: 249-255.
157. Lawson, L.J., V.H. Perry, P. Dri, et al. 1990. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39: 151-170.
158. Gehrmann, J., R.B. Banati & G.W. Kreutzberg 1993. Microglia in the immune surveillance of the brain: human microglia constitutively express HLA-DR molecules. J. Neuroimmunol. 48: 189-198.
159. Hart, A.D., A. Wyttenbach, V.H. Perry, et al. 2012. Age related changes in microglial phenotype vary between CNS regions: grey versus white matter differences. Brain. Behav. Immun. 26: 754-765.
160. Nacken, W., J. Roth, C. Sorg, et al. 2003. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc. Res. Tech. 60: 569-580.
161. Merkler, D., R. Böscke, B. Schmelting, et al. 2006. Differential macrophage / microglia activation in neocortical eae lesions in the marmoset monkey. Brain Pathol. 16: 117-123.
162. Buschmann, J.P., K. Berger, H. Awad, et al. 2012. Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. J. Mol. Neurosci. 48: 66-76.
163. Murugesan, N., D. Paul, Y. Lemire, et al. 2012. Active induction of experimental autoimmune encephalomyelitis by MOG35-55 peptide immunization is associated with differential responses in separate compartments of the choroid plexus. Fluids Barriers CNS 9: 15.
164. Howell, O.W., E.K. Schulz-Trieglaff, D. Carassiti, et al. 2015. Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space. Neuropathol. Appl. Neurobiol. 1-16.